Tscan Therapeutics (TCRX) EBITDA (2020 - 2025)
Tscan Therapeutics (TCRX) EBITDA from Jun 30, 2020 to Sep 30, 2025. The TTM Tscan Therapeutics (TCRX) EBITDA is -$148M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Tscan Therapeutics (TCRX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +32.58% |
| 3 Years TTM | +36.99% |
| 5 Years TTM | +63.17% |
| All Time TTM | +51.47% |
Annual EBITDA change of Tscan Therapeutics (TCRX)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$107M | -18.27% |
| 2024 | -$131M | +48.44% |
| 2023 | -$88M | +43.09% |
| 2022 | -$62M | +35.73% |
| 2021 | -$45M | +81.14% |
| 2020 | -$25M | N/A |